SCHEMBL19342136

SCHEMBL19342136

CC(C)(C)OC(=O)N1CCC(=N)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
ESR2 Q92731 1/20 0.48
NR1H2 P55055 1/20 0.47
HPGD P15428 1/20 0.46
HTT P42858 1/20 0.44
ATM Q13315 1/20 0.44
GPR119 Q8TDV5 3/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
RECQL P46063 1/20 0.44
EPHX1 P07099 1/20 0.44
ADORA1 P30542 1/20 0.43
MAPT P10636 2/20 0.43
KDM4E B2RXH2 1/20 0.43
THRB P10828 1/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
PTPN2 P17706 1/20 0.43
PTPN1 P18031 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14408021 0.93 HPGD (0.49) USP2SMN1; SMN2ESR2NR1H2HPGD
SCHEMBL1813321 0.82 USP2 (0.56) USP2SMN1; SMN2ESR2NR1H2HPGD
SCHEMBL3749225 0.82 USP2 (0.56) USP2SMN1; SMN2ESR2NR1H2HPGD
SCHEMBL27669441 0.82 USP2 (0.56) USP2SMN1; SMN2ESR2NR1H2HPGD
SCHEMBL31028 0.82 USP2 (0.56) USP2SMN1; SMN2ESR2NR1H2HPGD
SCHEMBL24818255 0.82 USP2 (0.56) USP2SMN1; SMN2ESR2NR1H2HPGD
SCHEMBL698803 0.81 USP2 (0.69) USP2SMN1; SMN2NR1H2HPGDHTT
SCHEMBL18294 0.81 USP2 (0.69) USP2SMN1; SMN2NR1H2HPGDHTT
SCHEMBL8436771 0.81 USP2 (0.55) USP2SMN1; SMN2ESR2NR1H2HPGD
SCHEMBL19459157 0.81 USP2 (0.55) USP2SMN1; SMN2ESR2NR1H2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117247347-A Preparation method of N-Boc-4-aminopiperidine 安徽昊帆生物有限公司 2023-12-19 CN claimed
CN-117247347-A Preparation method of N-Boc-4-aminopiperidine 安徽昊帆生物有限公司 2023-12-19 CN disclosed
CN-117247347-A Preparation method of N-Boc-4-aminopiperidine 安徽昊帆生物有限公司 2023-12-19 CN disclosed
EP-3891136-B1 4-HETEROARYLCARBONYL-N-(PHENYL OR HETEROARYL)PIPERIDINE-1-CARBOXAMIDES AS INHIBITORS OF TANKYRASES MERCK PATENT GMBH (DE) 2023-07-19 EP disclosed
WO-2023133524-A1 A PROCESS FOR SYNTHESIZING KETANSERIN TERRAN BIOSCIENCES, INC. (US) 2023-07-13 WO disclosed
US-10428024-B2 Piperidinyl derivatives MERCK PATENT GMBH (DE) 2019-10-01 US disclosed
US-20190135753-A1 PIPERIDINYL DERIVATIVES MERCK PATENT GMBH (DE) 2019-05-09 US disclosed
WO-2017156177-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. (US) 2017-09-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10428024-B2 Piperidinyl derivatives PDK1, PDK2, PDK3 USP2 3901/4885SMN1; SMN2 2643/4885ESR2 1142/4885
US-20190135753-A1 PIPERIDINYL DERIVATIVES PDK1, PDK2, PDK3 USP2 3901/4885SMN1; SMN2 2643/4885ESR2 1142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.